ALKEON CAPITAL MANAGEMENT LLC 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 4:12 pm Sale | 2024-12-31 | 13G | Keros Therapeutics, Inc. KROS | ALKEON CAPITAL MANAGEMENT LLC | 1,101,000 2.700% | -397,907 (-26.55%) | Filing |
| 2024-02-13 6:38 pm Purchase | 2023-12-31 | 13G | Keros Therapeutics, Inc. KROS | ALKEON CAPITAL MANAGEMENT LLC | 1,498,907 5.000% | 106,505 (+7.65%) | Filing |
| 2023-02-13 10:13 am Purchase | 2022-12-31 | 13G | Keros Therapeutics, Inc. KROS | ALKEON CAPITAL MANAGEMENT LLC | 1,392,402 5.100% | 1,392,402 (New Position) | Filing |